RT Journal Article
SR Electronic
T1 Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.12.08.416677
DO 10.1101/2020.12.08.416677
A1 Hongbing Zhang
A1 Zhiyuan Yang
A1 Jingyi Xiang
A1 Ziyou Cui
A1 Jianying Liu
A1 Cheng Liu
YR 2020
UL http://biorxiv.org/content/early/2020/12/09/2020.12.08.416677.abstract
AB Prevention of SARS-CoV-2 infection at the point of nasal entry is a novel strategy that has the potential to help contain the ongoing pandemic. Using our proprietary technologies, we have engineered a human antibody that recognizes SARS-CoV-2 S1 spike protein with an enhanced affinity for mucin to improve the antibody’s retention in respiratory mucosa. The modified antibody, when administered into mouse nostrils, was shown to block infection in mice that were exposed to high titer SARS-CoV-2 pseudovirus 10 hours after the initial antibody treatment. Our data show that the protection against SARS-CoV-2 infection is effective in both nasal and lung areas 7 days after viral exposure. The modified antibody is stable in a nasal spray formulation and maintains its SARS-CoV-2 neutralizing activity. Nasal spray of the modified antibody can be developed as an affordable and effective prophylactic product to protect people from infection by exposure to SARS-CoV-2 virus in the air.One-sentence summary A Fc-modified human antibody prevents SARS-CoV-2 viral infection via nasal administrationCompeting Interest StatementThe authors are all employees from biotechnology company Eureka Therapeutics, inc.